Patents Assigned to Inserm
  • Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
    Patent number: 9132173
    Abstract: The present invention relates to a vector for use in the treatment of Huntington's disease, which vector comprises a cholesterol 24-hydroxylase encoding nucleic acid.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: September 15, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes, Universite Evry Val d'essone, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jocelyne Caboche, Patrick Aubourg, Nathalie Cartier, Sandrine Betuing
  • LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER
    Publication number: 20150250770
    Abstract: Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample previously taken from a breast cancer patient, Classifying the breast cancer as likely to respond to treatment with everolimus if the LKB1 gene is under-expressed in said breast tumour sample.
    Type: Application
    Filed: July 1, 2013
    Publication date: September 10, 2015
    Applicants: CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD LYON 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle Treilleux, Thomas Bachelot, Muriel Le Romancer-Cherifi
  • CD31 peptides in the treatment of thrombotic and autoimmune disorders
    Patent number: 9127086
    Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: September 8, 2015
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • PAR2 agonists for use in the treatment or prevention of influenza virus type A infections
    Patent number: 9125861
    Abstract: Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRA)
    Inventors: Nathalie Vergnolle, Beatrice Riteau
  • Anti-human HER3 antibodies and uses thereof
    Patent number: 9127065
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
  • Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
    Patent number: 9125937
    Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: September 8, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE D'AUVERGNE CLERMONT 1, LABORATORIES CYCLOPHARMA
    Inventors: Jean-Michel Chezal, Frederic Dolle, Jean-Claude Madelmont, Aurelie Maisonial, Elisabeth Miot-Noirault, Nicole Moins, Janine Papon, Bertrand Kuhnast, Bertrand Tavitian, Raphael Boisgard
  • FKBP52-Tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
    Patent number: 9128104
    Abstract: The invention belongs to the fields of diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction. A direct interaction between proteins FKBP52 and Tau is reported. Herein are described methods for testing a subject thought to have or be predisposed to having a neurological disorder involving Tau dysfunction; and also for preventing or treating a neurological disorder involving Tau dysfunction in a subject in need thereof.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 8, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • Methods for the treatment of Prader-Willi-like syndrome or non-organic failure to thrive (NOFITT) feeding disorder using an agonist of the oxytocin receptor
    Patent number: 9125862
    Abstract: The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Rechereche Medicale (INSERM), Universite de la Mediterranee, CHU de Toulouse
    Inventors: Francoise Muscatelli, Maithe Tauber, Fabienne Schaller, Denise Thuilleaux
  • Method for expanding monocytes
    Patent number: 9125869
    Abstract: The invention relates to an ex vivo method for expanding monocytes, macrophages or dendritic cells, which method comprises inhibiting the expression or the activity of MafB and c-Maf in monocytes, macrophages or dendritic cells; and expanding the cells in the presence of at least one cytokine or an agonist of cytokine receptor signalling.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: September 8, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)
    Inventor: Michael Sieweke
  • Methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure
    Patent number: 9121858
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: September 1, 2015
    Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine, Centre Hospaitalier et de Nancy (CHU), Universite Paris Descartes
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 9121066
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: September 1, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Said Assou
  • Widespread gene delivery to the retina using systemic administration of AAV vectors
    Patent number: 9114161
    Abstract: The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: August 25, 2015
    Assignees: ASSOCIATION INSTITUT DE MYOLOGIE, GENETHON, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventor: Martine Barkats
  • Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin
    Patent number: 9115190
    Abstract: Detection sequences of periostin having from 6 to 30 amino acids and which include all or part of peptide sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3, or a homologous peptide sequence. Antibodies suitable for specifically recognizing minimally one of these detection sequences, including an anti-periostin antibody, are disclosed. Periostin detection and dosage processes and kits that use these antibodies are also disclosed. A periostin marker for early diagnosis, tracking and prognosis of pathologies that involve periostin, including benign osteolysis such as inflammatory diseases, including osteoarticular diseases, and malignant osteolysis, such as cancers with bone metastases, is provided.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 25, 2015
    Assignees: SYNARC SAS, INSERM
    Inventors: Patrick Garnero, Sylvain Contie, Nathalie Rousselot, Philippe Clezardin
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 9109227
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: August 18, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventor: Jean Valmier
  • Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma
    Patent number: 9107893
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: August 18, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Beirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Antagonists of GRASP55 for use as a medicament
    Patent number: 9107936
    Abstract: The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: August 18, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de la Mediterranee Aix-Marseille II
    Inventors: Michel Aurrand-Lions, Ana Zarubica
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA WITH INVARIANT NKT CELL AGONISTS
    Publication number: 20150224129
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with iNKT cell agonists.
    Type: Application
    Filed: October 1, 2013
    Publication date: August 13, 2015
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), INSTITUT PASTEUR DE LILLE, UNIVERSITÉ DE LILLE 1 - SCIENCES ET TECHNOLOGIES, UNIVERSITÉ DU DROIT ET DE LA SANTÉ LILLE 2, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Francois Trottein, Christelle Faveeuw, Stoyan Ivanov, Josette Fontaine
  • METHOD FOR ASSESSING A SUBJECT'S RISK OF HAVING A CARDIOVASCULAR DISEASE
    Publication number: 20150226749
    Abstract: The present invention relates to a method for assessing a subject's risk of having a cardiovascular disease comprising the step of measuring the level of IF1 in a body fluid sample obtained from said subject wherein the level of EF1 is negatively correlated with the risk of said subject of having cardiovascular disease.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
    Inventors: Laurent MARTINEZ, Bertrand PERRET, Annelise GENOUX
  • METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION
    Publication number: 20150225799
    Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.
    Type: Application
    Filed: April 24, 2015
    Publication date: August 13, 2015
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Jerome Galon, Franck Pages, Bernhard MLECNIK, Herve FRIDMAN
  • Bioprinting Station, Assembly Comprising Such Bioprinting Station and Bioprinting Method
    Publication number: 20150224291
    Abstract: Bioprinting station (1) comprising:—a Bioprinting device (4) adapted to deposit a pattern of biological material (2) onto an area of interest (3a) of a substrate (3),—an imaging system (15) adapted to acquire an image of the substrate (3) and to reveal on the acquired image the area of interest (3a) with respect to a remaining part (3b) of the substrate (3), the acquired image of the substrate (3) being processed so as to detect the revealed area of interest (3a) on the acquired image and to determine the pattern corresponding to the area of interest (3a) detected on the acquired image.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 13, 2015
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Fabien Guillemot, Sylvain Catros, Virginie Keriquel, Jean-Christophe Fricain